2019
Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges
Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Reviews 2019, 36: 70-87. PMID: 31101526, DOI: 10.1016/j.blre.2019.04.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute myeloid leukemiaPatient outcomesMyeloid leukemiaAllogeneic stem cell transplantationEtiology of AMLMinority of patientsStem cell transplantationAge-adjusted incidenceMost older individualsMyeloid progenitor cellsIntensive chemotherapyActive therapyClear etiologyOlder patientsRefractory diseaseSupportive careCurative therapyMedian agePoor prognosisShorter survivalCell transplantationDisease characteristicsEnvironmental DNA-damaging agentsMalignant disordersTherapeutic advances
2016
Factors affecting time to active therapy (AT) among patients (pts) with myelodysplastic syndromes (MDS) in a US electronic medical records (EMR) database.
Scott B, Kiselev P, Fliss A, Huang M, Steensma D, Ma X, Swern A, Sugrue M. Factors affecting time to active therapy (AT) among patients (pts) with myelodysplastic syndromes (MDS) in a US electronic medical records (EMR) database. Journal Of Clinical Oncology 2016, 34: e18548-e18548. DOI: 10.1200/jco.2016.34.15_suppl.e18548.Peer-Reviewed Original Research